5-苄氧基-1-BOC-吲哚-2-硼酸 | 850568-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-苄氧基-1-BOC-吲哚-2-硼酸
• 中文别名: 5-苄氧基-1-叔丁氧羰基吲哚-2-硼酸；5-苄氧基-1H-吲哚-2-硼酸N-BOC保护；5-苄氧基-1-Boc-吲哚-2-硼酸
• 英文名称: 1-tert-butyloxycarbonyl-5-benzyloxy-indole-2-boronic acid
• 英文别名: 5-benzyloxy-1-Boc-indole-2-boronic acid；{1-{[(1,1-dimethylethyl)oxy]carbonyl}-5-[(phenylmethyl)oxy]-1H-indol-2-yl}boronic acid；2-borono-5-benzyloxy-indole-1-carboxylic acid tert-butyl ester；(1-tert-butoxycarbonyl-5-benzyloxy-indol-2-yl)-boronic acid；[1-[(2-methylpropan-2-yl)oxycarbonyl]-5-phenylmethoxyindol-2-yl]boronic acid
• CAS: 850568-62-6
• 化学式: C₂₀H₂₂BNO₅
• 分子量: 367.209
• InChiKey: IQKGFXDPCFAYFP-UHFFFAOYSA-N

物化性质

• 熔点：
  106-110
• 沸点：
  564.7±60.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.68
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P271,P280,P312,P302+P352,P304+P340,P305+P351+P338,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  -20°C，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-Benzyloxy-1-BOC-indole-2-boronic acid
Product Name:
Synonyms: 5-Benzyloxy-1-t-butoxycarbonylindole-2-boronic acid; 5-Benzyloxy-1-BOC-2-indoleboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
5-Benzyloxy-1-BOC-indole-2-boronic acid
Ingredient name:
CAS number: 850568-62-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C20H22BNO5
Molecular weight: 367.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-苄氧基-1-BOC-吲哚-2-硼酸 在 potassium hydrogen difluoride 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以49%的产率得到Potassium (5-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-2-yl)trifluoroborate
  参考文献：
  名称：

  Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand

  摘要：

  提出了合成钌吡啶卡巴唑半夹心配合物的一般路线，并应用于合成十六种新化合物，其中许多化合物具有调节蛋白激酶抑制特性的性能。例如，在吡啶部分引入氟原子可使对糖原合酶激酶3的结合亲和力增加近一个数量级。这些数据显示补充了循环伏安实验和蛋白质共结晶学研究。

  DOI：

  10.1039/b700433h
• 作为产物：
  描述：

  5-苄氧基吲哚 在 4-二甲氨基吡啶 、 硼酸三异丙酯 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 5-苄氧基-1-BOC-吲哚-2-硼酸
  参考文献：
  名称：

  Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand

  摘要：

  提出了合成钌吡啶卡巴唑半夹心配合物的一般路线，并应用于合成十六种新化合物，其中许多化合物具有调节蛋白激酶抑制特性的性能。例如，在吡啶部分引入氟原子可使对糖原合酶激酶3的结合亲和力增加近一个数量级。这些数据显示补充了循环伏安实验和蛋白质共结晶学研究。

  DOI：

  10.1039/b700433h

文献信息

• [EN] FARNESOID X RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE FARNÉSOÏDE X
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009005998A1

  公开（公告）日：2009-01-08

  The present invention relates to famesoid X receptors (FXR, NR1H4) FXR is a member of the nuclear receptor class of ligand-activate transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome

  本发明涉及法内索德X受体（FXR，NR1H4）。FXR是配体激活的转录因子核受体类的一个成员。更具体地说，本发明涉及作为FXR激动剂的化合物，包含该化合物的药物制剂，以及同一治疗用途。新颖的异恶唑化合物被披露作为药物组合物的一部分，用于治疗由FXR活性降低介导的状况，如肥胖、糖尿病、胆汁淤积性肝病、肝纤维化和代谢综合征。
• Kinase antagonists
  申请人：Knight A. Zachary

  公开号：US20070293516A1

  公开（公告）日：2007-12-20

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.

  本发明提供了一种新型化合物，它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR，或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。
• Discovery and structure–activity relationship studies of indole derivatives as liver X receptor (LXR) agonists
  作者：Farid Bakir、Sunil Kher、Madhavi Pannala、Norma Wilson、Trang Nguyen、Ila Sircar、Kei Takedomi、Chiaki Fukushima、James Zapf、Kui Xu、Shao-Hui Zhang、Juping Liu、Lisa Morera、Lisa Schneider、Naoki Sakurai、Rick Jack、Jie-Fei Cheng

  DOI：10.1016/j.bmcl.2007.03.076

  日期：2007.6

  A structurally novel liver X receptor (LXR) agonist (1) was identified from internal compound collection utilizing the combination of structure-based virtual screening and high-throughput gene profiling. Compound 1 increased ABCA1 gene expression by eightfold and SREBP1c by threefold in differentiated THP-1 macrophage cell lines. Confirmation of its agonistic activity against LXR was obtained in the

  利用基于结构的虚拟筛选和高通量基因分析相结合的方法，从内部化合物收集中鉴定出一种结构新颖的肝X受体（LXR）激动剂（1）。在分化的THP-1巨噬细胞系中，化合物1使ABCA1基因表达增加了8倍，而SREBP1c增加了3倍。在辅助因子募集和报告基因反式激活测定中获得了其对LXR的激动活性的证实。描述了对化合物1的构效关系研究。
• 7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: Design, synthesis, and biological activity
  作者：Terry V. Hughes、Stuart L. Emanuel、Harold R. O’Grady、Peter J. Connolly、Catherine Rugg、Angel R. Fuentes-Pesquera、Prabha Karnachi、Richard Alexander、Steven A. Middleton

  DOI：10.1016/j.bmcl.2008.07.090

  日期：2008.9

  A novel series of 7-[1H-indol-2-yl]-2,3-dihydro-isoindol-1-ones designed to be inhibitors of VEGF-R2 kinase was synthesized and found to potently inhibit VEGF-R2 and Aurora-A kinases. The structure-based design, synthesis, and initial SAR of the series are discussed.

  合成了一系列新型的7- [1H-吲哚-2-基] -2,3-二氢-异吲哚-1-酮，旨在作为VEGF-R2激酶的抑制剂，并有效抑制VEGF-R2和Aurora-A。激酶。讨论了该系列的基于结构的设计，合成和初始SAR。
• FXR agonist activity of conformationally constrained analogs of GW 4064
  作者：Adwoa Akwabi-Ameyaw、Jonathan Y. Bass、Richard D. Caldwell、Justin A. Caravella、Lihong Chen、Katrina L. Creech、David N. Deaton、Kevin P. Madauss、Harry B. Marr、Robert B. McFadyen、Aaron B. Miller、Frank Navas、Derek J. Parks、Paul K. Spearing、Dan Todd、Shawn P. Williams、G. Bruce Wisely

  DOI：10.1016/j.bmcl.2009.06.062

  日期：2009.8

  Two series of conformationally constrained analogs of the FXR agonist GW 4064 1 were prepared. Replacement of the metabolically labile stilbene with either benzothiophene or naphthalene rings led to the identification of potent full agonists 2a and 2g.

  制备了两个系列的FXR激动剂GW 4064 1的构象约束类似物。用苯并噻吩或萘环取代代谢不稳定的二苯乙烯导致了强有力的全激动剂2a和2g的鉴定。